Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

被引：0
|
作者：
Cohen, Adam D. [1 ]
Garfall, Alfred L. [2 ]
Susanibar-Adaniya, Sandra Patricia [2 ]
Vogl, Dan T. [2 ]
Waxman, Adam [2 ]
De Mesa, Oksana [2 ]
Kane, Elizabeth [3 ]
Nichols, Charles [4 ]
Razzo, Beatrice [2 ]
Stadtmauer, Edward A. [2 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
653
引用
收藏
页码：12628 / 12629
页数：2
相关论文
共 50 条
  • [31] High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients With Multiple Myeloma. Results of a Phase II Prospective Study
    Sahebi, Firoozeh
    Krishnan, Amrita
    Farol, Leonardo
    Cai, Ji-Lian
    Somlo, George
    Popplewell, Leslie
    Spielberger, R.
    Kogut, Neil Martin
    Karanes, Chatchada
    Ruel, Christopher
    Frankel, Paul
    Reburiano, Eunicia
    O'Donnell, Margret
    Forman, Stephen
    BLOOD, 2010, 116 (21) : 994 - 995
  • [32] The efficacy of Salvage Autologous Stem Cell Transplant for Patients With Multiple Myeloma Who Received Maintenance Therapy Post an Initial Transplant
    King, Justin
    Fiala, Mark
    Kohnen, Daniel
    Stockerl-Goldstein, Keith
    Wildes, Tanya
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E71
  • [33] Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant
    Martin, Petra
    Ye, Rebecca
    Kolk, Merle
    Ferrari, Nicole
    Caimi, Paolo
    Metheny, Leland
    Driscoll, James
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2018, 132
  • [34] Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).
    Thomas, Sheeba K.
    George, Jamie S.
    de Partovi, Claudia M. Morales
    Feng, Lei
    Morphey, Ashley S.
    Becnel, Melody R.
    Kaufman, Gregory P.
    Lee, Hans C.
    Manasanch, Elisabet Esteve
    Patel, Krina K.
    Pasvolsky, Oren
    Ye, Jing Christine
    Amini, Behrang
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Crumpton, Brandon N.
    Stafford, Mildred M.
    Johnson, Ralph J., III
    Weber, Donna M.
    Orlowski, Robert Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
    Thomas, Sheeba K.
    Shah, Jatin J.
    Morphey, Ashley N.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Patel, Krina K.
    Miller, Carla P.
    Phillips, Suzanne
    Crumpton, Brandon N.
    Johnson, Ralph J.
    Feng, Lei
    Iyer, Swaminathan P.
    Amini, Behrang
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD, 2018, 132
  • [36] Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
    Uy, G. L.
    Goyal, S. D.
    Fisher, N. M.
    Oza, A. Y.
    Tomasson, M. H.
    Stockerl-Goldstein, K.
    DiPersio, J. F.
    Vij, R.
    BONE MARROW TRANSPLANTATION, 2009, 43 (10) : 793 - 800
  • [37] Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
    G L Uy
    S D Goyal
    N M Fisher
    A Y Oza
    M H Tomasson
    K Stockerl-Goldstein
    J F DiPersio
    R Vij
    Bone Marrow Transplantation, 2009, 43 : 793 - 800
  • [38] A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
    Fuchida, Shin-ichi
    Sunami, Kazutaka
    Matsumoto, Morio
    Okumura, Hirokazu
    Murayama, Tohru
    Miyamoto, Toshihiro
    Otsuka, Eichi
    Fujishima, Naohito
    Izumi, Tohru
    Tamaki, Shigehisa
    Hiramatsu, Yasushi
    Kuroda, Yoshiaki
    Shimazaki, Chihiro
    Akashi, Koichi
    Harada, Mine
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 107 - 114
  • [39] A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
    Shin-ichi Fuchida
    Kazutaka Sunami
    Morio Matsumoto
    Hirokazu Okumura
    Tohru Murayama
    Toshihiro Miyamoto
    Eichi Otsuka
    Naohito Fujishima
    Tohru Izumi
    Shigehisa Tamaki
    Yasushi Hiramatsu
    Yoshiaki Kuroda
    Chihiro Shimazaki
    Koichi Akashi
    Mine Harada
    International Journal of Hematology, 2019, 109 : 107 - 114
  • [40] A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    Terpos, Evangelos
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Kanellias, Nikolaos
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Papaiakovou, Evangelos Eleutherakis
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Dimopoulos, Meletios A.
    BLOOD, 2022, 140 : 12616 - 12617
12345